| 叶丽,陈彬,王玲.特发性矮小症儿童血清IGFBP-3、25(OH)D、Nesfatin-1和骨钙素水平及其临床意义.[J].中南医学科学杂志.,2024,(1):106-109. |
| 特发性矮小症儿童血清IGFBP-3、25(OH)D、Nesfatin-1和骨钙素水平及其临床意义 |
| Serum IGFBP-3,25(OH)D, Nesfatin-1, and osteocalcin levels in children with idiopathic short stature and their clinical significance |
| 投稿时间：2023-05-16 修订日期：2023-12-07 |
| DOI：10.15972/j.cnki.43-1509/r.2024.01.025 |
| 中文关键词: 特发性矮小症 IGFBP-3 25(OH)D Nesfatin-1 骨钙素 [ |
| 英文关键词:idiopathic short stature IGFBP-3 25(OH)D Nesfatin-1 osteocalcin |
| 基金项目:福建医科大学启航基金项目(2020QH1309) |
|
| 摘要点击次数: 221 |
| 全文下载次数: 290 |
| 中文摘要: |
| 目的探讨特发性矮小症(ISS)儿童血清胰岛素生长因子结合蛋白-3(IGFBP-3)、25羟维生素D[25(OH)D]、摄食抑制因子-1(Nesfatin-1)、骨钙素水平及其临床意义。 方法选取矮小症儿童286例为观察组,其中ISS组152例,生长激素缺乏(GHD)组134例；同时选取健康儿童100例为对照组。比较各组血清IGFBP-3、25(OH)D、Nesfatin-1、骨钙素水平差异,及其与体格发育等临床特征的关系。 结果观察组儿童身高、骨龄指数、血清IGFBP-3、25(OH)D、骨钙素水平低于对照组,而Nesfatin-1高于对照组(P＜0.05)。ISS组儿童身高、骨龄指数、血清IGFBP-3、25(OH)D、骨钙素水平高于GHD组,而Nesfatin-1低于GHD组(P＜0.05)。血清IGFBP-3、25(OH)D和骨钙素水平身高≥125 cm儿童高于＜125 cm儿童、骨龄指数≥0.90儿童高于＜0.90儿童；而Nesfatin-1趋势相反(P＜0.05)。ISS儿童血清IGFBP-3、25(OH)D、骨钙素与儿童身高、骨龄指数呈正相关(P＜0.05),Nesfatin-1与儿童身高、骨龄指数呈负相关(P＜0.05)。 结论与健康儿童相比,ISS儿童血清IGFBP-3、25(OH)D、骨钙素水平较低,Nesfatin-1水平较高,可能与儿童体格发育存在相关性。 |
| 英文摘要: |
| AimTo investigate the serum levels of insulin-like growth factor binding protein-3 (IGFBP-3), 25 hydroxyvitamin D[25(OH)D], food intake inhibitory factor-1 (Nesfatin-1), and osteocalcin in children with idiopathic short stature (ISS) and their clinical significance. Methods286 children with short stature were selected as the observation group, including 152 cases in the ISS group and 134 cases in the growth hormone deficiency (GHD) group. Meanwhile, 100 healthy children were selected as the control group. The differences in serum IGFBP-3,25(OH)D, Nesfatin-1, and osteocalcin levels among different groups were compared, and their relationship with physical development was analyzed. ResultsThe height, bone age index, serum IGFBP-3,25(OH)D, and osteocalcin levels of children in the observation group were lower than those in the control group, while Nesfatin-1 was higher than that in the control group (P＜0.05). The height, bone age index, serum IGFBP-3,25(OH)D, and osteocalcin of children in the ISS group were higher than those in the GHD group, while Nesfatin-1 was lower than that in the GHD group (P＜0.05). Serum IGFBP-3,25(OH)D, and osteocalcin levels were higher in children with a height of ≥125 cm than those in children with a height of＜125 cm, and higher in children with a bone age index of ≥ 0.90 than those in children with a height of ＜0.90. However, the trend of Nesfatin-1 is opposite (P＜0.05). The serum levels of IGFBP-3,25(OH)D, and osteocalcin in children with ISS were positively correlated with their height and bone age index (P＜0.05), while Nesfatin-1 was negatively correlated with their height and bone age index (P＜0.05). ConclusionCompared with healthy children, the serum levels of IGFBP-3,25(OH)D, and osteocalcin in children with ISS are lower, while the levels of Nesfatin-1 are higher, which may be related to the physical development of children. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|